Frank H J, Levin E R, Hu R M, Pedram A
Department of Medicine and Pharmacology, University of California, Irvine 92717.
Endocrinology. 1993 Sep;133(3):1092-7. doi: 10.1210/endo.133.3.8365355.
Hyperinsulinemia has been implicated as a separate risk factor for the development of accelerated cardiovascular disease, but the mechanism is unknown. Recently, we and several other groups have shown that insulin stimulates the production and secretion of the vasoconstrictor peptide endothelin-1 (ET-1) from vascular endothelial cells, and hyperinsulinemia results in increased plasma ET levels in vivo. However, the interactive effects of diabetes, insulin, and glucose on ET target tissues, like those on vascular smooth muscle cells (VSMC), are not well defined. In these studies, we examined the effects of the diabetic factors on ET receptors and [3H]thymidine incorporation into cultured cells prepared from control, streptozocin-diabetic, insulin-treated diabetic, and hyperinsulinemic rats. Scatchard analysis of saturation binding studies revealed a 2-fold increase in ET receptor number in normal VSMC treated in vitro with insulin, whereas glucose had no significant effect. Neither treatment affected receptor affinity. Similarly, aortic smooth muscle cells, brain capillary pericytes, and kidney afferent arteriolar smooth muscle cells from rats made hyperinsulinemic in vivo each showed approximately a 2-fold increase in receptor number. This increase in receptor density probably resulted from the stimulation of receptor protein production, because insulin caused a maximal 2.3 +/- 0.3 (+/- SEM) fold increase in the ETA receptor mRNA expressed in cultured VSMC by 4 h. Both insulin and ET significantly increased thymidine incorporation in aortic VSMC, but ET-1 was much more potent in this regard. However, the combined effects of insulin plus ET-1 resulted in a 10-fold increase in this index of cell proliferation, significantly different from the effects of either peptide alone. We postulate that hyperinsulinemia in vivo may potentiate ET release and receptor-mediated action, thereby contributing to vascular disease in the setting of diabetes.
高胰岛素血症被认为是加速心血管疾病发生的一个独立危险因素,但其机制尚不清楚。最近,我们和其他几个研究小组发现,胰岛素可刺激血管内皮细胞产生和分泌血管收缩肽内皮素-1(ET-1),高胰岛素血症会导致体内血浆ET水平升高。然而,糖尿病、胰岛素和葡萄糖对ET靶组织(如血管平滑肌细胞,VSMC)的相互作用尚未明确。在这些研究中,我们检测了糖尿病相关因素对ET受体以及[3H]胸腺嘧啶核苷掺入从对照、链脲佐菌素诱导糖尿病、胰岛素治疗糖尿病和高胰岛素血症大鼠制备的培养细胞中的影响。对饱和结合研究进行Scatchard分析发现,体外经胰岛素处理的正常VSMC中ET受体数量增加了2倍,而葡萄糖无显著影响。两种处理均不影响受体亲和力。同样,体内诱导产生高胰岛素血症的大鼠的主动脉平滑肌细胞、脑毛细血管周细胞和肾入球小动脉平滑肌细胞,其受体数量均显示出约2倍的增加。受体密度的增加可能是由于受体蛋白产生受到刺激,因为胰岛素在4小时内使培养的VSMC中表达的ETA受体mRNA最大增加了2.3±0.3(±SEM)倍。胰岛素和ET均显著增加主动脉VSMC中的胸腺嘧啶核苷掺入,但在这方面ET-1的作用更强。然而,胰岛素加ET-1的联合作用使该细胞增殖指标增加了10倍,与单独使用任何一种肽的作用显著不同。我们推测,体内高胰岛素血症可能会增强ET的释放和受体介导的作用,从而在糖尿病情况下导致血管疾病。